Increased levels of thioredoxin and thioredoxin reductase in diabetic patients with coronary artery disease

The prevalence of type 2 diabetes (DM) is considered an important risk factor for coronary artery disease (CAD). This study aimed to evaluate the relationship between CAD and thioredoxin (Trx) system and novel lipid indices in DM patients. In this case-control study, serum levels of Trx, Thioredoxin reductase (TrxR), Thioredoxin interacting protein (TXNIP), and novel lipid indices in DM undergoing coronary angiography (CAG) was investigated. A total of 99 patients with DM were included in the study (DM + CAD n: 62 and DM n: 37. Serum levels of intracellular antioxidant defense molecules, Trx and TrxR were significantly increased in patients with CAD+DM. However, TXNIP serum levels did not differ significantly between DM+CAD and DM groups. Also, there was a significant positive correlation between Trx and TXNIP (p

PDF

___

Wang DS, Yan LY, Yang DZ, et al. Formononetin ameliorates myocardial ischemia/reperfusion injury in rats by suppressing the ROS-TXNIP-NLRP3 pathway. Biochem Biophys Res Commun. 2020; 4: pii: S0006-291X (20)30436-8.
Rong J, Xu X, Xiang Y, et al. Thioredoxin-interacting protein promotes activation and inflammation of monocytes with DNA demethylation in coronary artery disease. J Cell Mol Med. 2020;24:3560-3571.
Poljsak B, Milisav I. The neglected significance of "antioxidative stress". Oxid Med Cell Longev. 2012;2012:480895.
Zschauer TC, Matsushima S, Altschmied J, et al. Interacting with thioredoxin1-disease or no disease? Antioxid Redox Signal. 2013;20:18:1053-62.
Lee S, Kim SM, Lee RT. Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal. 2013;1;18:1165-207.
Oliveira PVS, Laurindo FRM. Implications of plasma thiol redox in disease. Clin Sci (Lond). 2018;21;132:1257-80.
Mahmood DF, Abderrazak A, El Hadri K, et al. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal. 2013;10;19:1266-303.
Ren X, Zou L, Lu J, Holmgren A. Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic. Free Radic Biol Med. 2018;1;127:238-47.
Miller CG, Holmgren A, Arnér ESJ, et al. NADPH-dependent and -independent disulfide reductase systems. Free Radic Biol Med. 20181;127:248-61.
Gu C, Liu S, Wang H, Dou H. Role of the thioredoxin interacting protein in diabetic nephropathy and the mechanism of regulating NOD-like receptor protein 3 inflammatory corpuscle. Int J Mol Med. 2019;43:2440-50..
Kariž S, Mankoč S, Petrovič D. Association of thioredoxin reductase 2 (TXNRD2) gene polymorphisms with myocardial infarction in Slovene patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2015;108:323-8.
Zhao X, Zhang Y, Li X, et al. Variations of thioredoxin system contributes to increased susceptibility to apoptosis in cardiomyocytes of type 2 diabetic rats. Acta Biochim Biophys Sin (Shanghai). 2014;46:318-29.
El Hadri K, Mahmood DF, Couchie D, et al. Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:1445-52.
Yoshihara E, Masaki S, Matsuo Y, et al. Thioredoxin/Txnip: redoxisome, as a redox switch for the pathogenesis of diseases. Front Immunol. 2014;9;4- 514.
Whayne TF Jr, Parinandi N, Maulik N. Thioredoxins in cardiovascular disease. Can J Physiol Pharmacol. 2015;93:903-11.
Kamangar F, Islami F.Sample size calculation for epidemiologic studies: principles and methods. Arch Iran Med. 2013;16:295-300.
El Hadri K, Mahmood DF, Couchie D, et.al. Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:1445-52.
Chen B, Meng L, Shen T, et al. Thioredoxin attenuates oxidized low-density lipoprotein induced oxidative stress in human umbilical vein endothelial cells by reducing NADPH oxidase activity. Biochem Biophys Res Commun. 2017;2;490:1326-33.
Cao G, Llambí HG, Muller A, et al. Rosuvastatin increases myocardial microvessels in SHR rats. Role of thioredoxin-1 and peroxiredoxin-2 expression. Int J Cardiol. 2014;1;174:153-5.
Lu J, Holmgren A. The thioredoxin antioxidant system. Free Radic Biol Med. 2014;66:75-87.
Harper MT. Auranofin, a thioredoxin reductase inhibitor, causes platelet death through calcium overload. Platelets. 2019;30:98-104.
Roder C, Thomson MJ. Auranofin: repurposing an old drug for a golden new age. Drugs R D. 2015;15:13-20.
Canesi F, Mateo V, Couchie D, et al. Thioredoxin-mimetic peptide exerts potent anti-inflammatory, anti-oxidant and atheroprotective effects in ApoE2. Ki mice fed high fat diet. Cardiovasc Res. 2019;1;115:292-301.
Cohen-Kutner M, Khomsky L, Trus M, Thioredoxin-mimetic peptide CB3 lowers MAPKinase activity in the Zucker rat brain. Redox Biol. 2014;9;2:447-56.
Yilmaz N. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Arch Med Sci. 2012;29;8:138-53.
. Tinkov AA, Bjørklund G, Skalny AV, et al. The role of the thioredoxin/ thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker? Cell Mol Life Sci. 2018; 75:1567-86.
Hou R, Shen M, Wang R, et al. Thioredoxin1 Inactivation Mediates the Impairment of Ischemia-Induced Angiogenesis and Further Injury in Diabetic Myocardium Vasc Res. 2020;57:76-85.